Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Zhendong Chen"'
Autor:
Liang Sun, Zhengyi Wu, Cairong Dong, Shian Yu, He Huang, Zhendong Chen, Zhipeng Wu, Xiangbao Yin
Publikováno v:
BMC Medical Genomics, Vol 16, Iss 1, Pp 1-19 (2023)
Abstract Objective Hepatocellular carcinoma (HCC) immunotherapy is a focus of current research. We established a model that can effectively predict the prognosis and efficacy of HCC immunotherapy by analyzing the immune genes of HCC. Methods Through
Externí odkaz:
https://doaj.org/article/73cfcf9b062d4926831c322bd92e9b9d
Autor:
Chengyou Du, Guoliang Shao, Yajin Chen, Yabing Guo, Jianbing Wu, Aibing Xu, Yuxian Bai, Ming Huang, Baocai Xing, Bixiang Zhang, Tao Yin, Yong Yang, Yan Wang, Yilei Mao, Xuetao Shi, Mingxia Chen, Yinying Lu, Weidong Jia, Zhenggang Ren, Jiuwei Cui, Zhenyuan Gao, Chao Liu, Wei Yang, Yunfeng Shan, Shanzhi Gu, Zhendong Chen, Qiu Li, Yanru Qin, Guowen Yin, Jianming Xu, Jian Wu, Shundong Cang, Feng Xia, Baorui Liu, Junye Wang, Jinhai Wang, Gao-Jun Teng, Hui Zhou, Jia Fan, Zhiqiang Meng
Publikováno v:
The Lancet Oncology. 22:977-990
Summary Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase
Autor:
Zhendong Chen, Zishu Wang, Helong Zhang, Ping Yang, Shanzhi Gu, Feng Chen, Zhenyu You, Bo Zhu, Yinying Lu, Feng Bi, Zhenggang Ren, Xi Chen, Zhendong Zheng, Xiaoli Xin, Junhui Chen, Aibing Xu, Jieer Ying, Xiaoyu Wen, Chengxu Cui, Liqing Wu, Jinlu Shan, Yuxian Bai, Hongming Pan, Jufeng Wang, Jian Wu, Li Xu, Zhiqiang Meng, Meng Qiu, Xiufeng Liu, Shukui Qin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(27)
PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-l
Autor:
Linna Wang, Xiaoli Chai, Xiaoyan Lin, Zhenggang Ren, Weijia Fang, Zhendong Chen, Jianping Xiong, Jianjun Zou, Enxiao Li, Ping Yan, Xiaoming Chen, Lin Yang, Shukui Qin, Zhiqiang Meng, Hong Zhu, Yuxian Bai
Publikováno v:
Liver Cancer, Pp 375-384 (2021)
Liver Cancer
Liver Cancer
Introduction: In a multicenter, open-label, parallel-group, randomized, phase 2 study for pretreated advanced hepatocellular carcinoma (HCC), camrelizumab showed potent antitumor activity and acceptable safety profile. The aim of this report was to p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82ccfc60bef68f78cdf6a508cd2b59d0
https://www.karger.com/Article/FullText/516470
https://www.karger.com/Article/FullText/516470
Autor:
Zhenggang Ren, Xiao Zhang, Ying Liu, Linna Wang, Jianping Xiong, Hui Li, Jianjun Zou, Xiaojing Zhang, Shukui Qin, Zhendong Chen, Zhiqiang Meng
Publikováno v:
Drug Design, Development and Therapy
Hui Li,1,* Shukui Qin,1,* Ying Liu,2 Zhendong Chen,3 Zhenggang Ren,4 Jianping Xiong,5 Zhiqiang Meng,6 Xiao Zhang,7 Linna Wang,7 Xiaojing Zhang,7 Jianjun Zou7 1Department of Medical Oncology Center, Bayi Affiliated Hospital, Nanjing University of Chin
Autor:
Weijia Fang, Zhiqiang Meng, Xiaoli Chai, Jianping Xiong, Zhendong Chen, Zhenggang Ren, Enxiao Li, Feng Wang, Jianjun Zou, Xiaoyan Lin, Ping Yan, Shukui Qin, Xiaoming Chen, Lin Yang, Xinchen Sun, Linna Wang, Hong Zhu, Yuxian Bai
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Background Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an immune checkpoint inhibitor, bu
Autor:
Jianming Ying, Hongming Pan, Lunxu Liu, Zhiqiang Meng, Zhendong Chen, F. Bi, Helong Zhang, Ping Yang, Shanzhi Gu, Zishu Wang, Xi Chen, A. Xu, Yiping Lu, Shukui Qin, Yuxian Bai
Publikováno v:
Annals of Oncology. 32:S820
Autor:
J.J. Zou, Zhiqiang Meng, W. Fang, X. Lin, X.L. Chai, Zhendong Chen, Yuxian Bai, Ling Yang, L. Wang, Jianping Xiong, Zhenggang Ren, C. Chen, Shukui Qin, Xi Chen, E. Li, Hong Zhu
Publikováno v:
Annals of Oncology. 31:S689-S690
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundEmerging clinical data suggest that an immune checkpoint inhibitor in combination with an antiangiogenic agent is a reasonable strategy for multiple malignancies. We assessed the combination of camrelizumab with apatinib in pretreated advan
Autor:
Qiu Li, Y. Chen, Jianwei Fan, Baorui Liu, C. Du, Yuxian Bai, A. Xu, Zhenggang Ren, Y. Guo, Minhu Chen, G. Shao, S. Cang, Yiping Lu, Zhendong Chen, Yongyan Wang, Yunpeng Yang, H. Zhou, Jianrong Xu
Publikováno v:
Annals of Oncology. 31:S1287